{"Content: ":"HGC019 is a mRNA based COVID-19 vaccine candidate being developed by Gennova Biopharmaceuticals and HDT Bio Corp. with active support from NIH under The Indo-US Vaccine Action Program (VAP) and Department of Biotechnology, India.[1] The phase-I trials began in February 2021 after receiving permission from Drugs Controller General of India (DGCI),[2][3] to evaluate the safety and immunogenicity of the vaccine candidate in about 120 participants consisting of age group (18-70) years.[4] The phase-II trials is planned to conduct with 500 participants from the age group (18-75) years.[4] On 24 August 2021, the Drugs Controller General of India gave a go ahead for phase II/III trials after it was found to safe, tolerable, and immunogenic in the phase I trial results.[5][6][7] The company has received a funding of \u20b9250 crore (around US$33.5 million) from Government of India based on the clinical trials progress.[8]  This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.","Title":"HGC019 - Wikipedia","KeyID":"11160","URL":"https://en.wikipedia.org/wiki/HGC019"}